Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ryotaro Iwasaki is active.

Publication


Featured researches published by Ryotaro Iwasaki.


Journal of Experimental Medicine | 2010

The Blimp1–Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis

Yoshiteru Miyauchi; Ken Ninomiya; Hiroya Miyamoto; Akemi Sakamoto; Ryotaro Iwasaki; Hiroko Hoshi; Kana Miyamoto; Wu Hao; Shigeyuki Yoshida; Hideo Morioka; Kazuhiro Chiba; Shigeaki Kato; Takeshi Tokuhisa; Mitinori Saitou; Yoshiaki Toyama; Toshio Suda; Takeshi Miyamoto

Controlling osteoclastogenesis is critical to maintain physiological bone homeostasis and prevent skeletal disorders. Although signaling activating nuclear factor of activated T cells 1 (NFATc1), a transcription factor essential for osteoclastogenesis, has been intensively investigated, factors antagonistic to NFATc1 in osteoclasts have not been characterized. Here, we describe a novel pathway that maintains bone homeostasis via two transcriptional repressors, B cell lymphoma 6 (Bcl6) and B lymphocyte–induced maturation protein-1 (Blimp1). We show that Bcl6 directly targets ‘osteoclastic’ molecules such as NFATc1, cathepsin K, and dendritic cell-specific transmembrane protein (DC-STAMP), all of which are targets of NFATc1. Bcl6-overexpression inhibited osteoclastogenesis in vitro, whereas Bcl6-deficient mice showed accelerated osteoclast differentiation and severe osteoporosis. We report that Bcl6 is a direct target of Blimp1 and that mice lacking Blimp1 in osteoclasts exhibit osteopetrosis caused by impaired osteoclastogenesis resulting from Bcl6 up-regulation. Indeed, mice doubly mutant in Blimp1 and Bcl6 in osteoclasts exhibited decreased bone mass with increased osteoclastogenesis relative to osteoclast-specific Blimp1-deficient mice. These results reveal a Blimp1–Bcl6–osteoclastic molecule axis, which critically regulates bone homeostasis by controlling osteoclastogenesis and may provide a molecular basis for novel therapeutic strategies.


Journal of Experimental Medicine | 2007

Reactive oxygen species induce chondrocyte hypertrophy in endochondral ossification

Kozo Morita; Takeshi Miyamoto; Nobuyuki Fujita; Yoshiaki Kubota; Keisuke Ito; Keiyo Takubo; Kana Miyamoto; Ken Ninomiya; Toru Suzuki; Ryotaro Iwasaki; Mitsuru Yagi; Hironari Takaishi; Yoshiaki Toyama; Toshio Suda

Chondrocyte hypertrophy during endochondral ossification is a well-controlled process in which proliferating chondrocytes stop proliferating and differentiate into hypertrophic chondrocytes, which then undergo apoptosis. Chondrocyte hypertrophy induces angiogenesis and mineralization. This step is crucial for the longitudinal growth and development of long bones, but what triggers the process is unknown. Reactive oxygen species (ROS) have been implicated in cellular damage; however, the physiological role of ROS in chondrogenesis is not well characterized. We demonstrate that increasing ROS levels induce chondrocyte hypertrophy. Elevated ROS levels are detected in hypertrophic chondrocytes. In vivo and in vitro treatment with N-acetyl cysteine, which enhances endogenous antioxidant levels and protects cells from oxidative stress, inhibits chondrocyte hypertrophy. In ataxia telangiectasia mutated (Atm)–deficient (Atm−/−) mice, ROS levels were elevated in chondrocytes of growth plates, accompanied by a proliferation defect and stimulation of chondrocyte hypertrophy. Decreased proliferation and excessive hypertrophy in Atm−/− mice were also rescued by antioxidant treatment. These findings indicate that ROS levels regulate inhibition of proliferation and modulate initiation of the hypertrophic changes in chondrocytes.


Journal of Experimental Medicine | 2011

Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization

Kana Miyamoto; Shigeyuki Yoshida; Miyuri Kawasumi; Kazuaki Hashimoto; Tokuhiro Kimura; Yuiko Sato; Tami Kobayashi; Yoshiteru Miyauchi; Hiroko Hoshi; Ryotaro Iwasaki; Hiroya Miyamoto; Wu Hao; Hideo Morioka; Kazuhiro Chiba; Takashi Kobayashi; Hisataka Yasuda; Josef M. Penninger; Yoshiaki Toyama; Toshio Suda; Takeshi Miyamoto

The mobilization of hematopoietic stem cells does not require osteoclasts, which may even have an inhibitory effect.


Journal of Bone and Mineral Research | 2007

Induction of DC-STAMP by alternative activation and downstream signaling mechanisms.

Mitsuru Yagi; Ken Ninomiya; Nobuyuki Fujita; Toru Suzuki; Ryotaro Iwasaki; Kozo Morita; Naobumi Hosogane; Koichi Matsuo; Yoshiaki Toyama; Toshio Suda; Takeshi Miyamoto

DC‐STAMP is essential for fusion of osteoclasts and foreign body giant cells; however, it is not known whether dc‐stamp expression in these two cell types is differentially regulated. Here, we show that dc‐stamp expression and cell–cell fusion are regulated in a cell type–specific manner.


Journal of Bone and Mineral Research | 2012

Osteoclast stimulatory transmembrane protein and dendritic cell–specific transmembrane protein cooperatively modulate cell–cell fusion to form osteoclasts and foreign body giant cells

Hiroya Miyamoto; Takayuki Suzuki; Yoshiteru Miyauchi; Ryotaro Iwasaki; Tami Kobayashi; Yuiko Sato; Kana Miyamoto; Hiroko Hoshi; Kazuaki Hashimoto; Shigeyuki Yoshida; Wu Hao; Tomoaki Mori; Hiroya Kanagawa; Eri Katsuyama; Atsuhiro Fujie; Hideo Morioka; Morio Matsumoto; Kazuhiro Chiba; Motohiro Takeya; Yoshiaki Toyama; Takeshi Miyamoto

Cell–cell fusion is a dynamic phenomenon promoting cytoskeletal reorganization and phenotypic changes. To characterize factors essential for fusion of macrophage lineage cells, we identified the multitransmembrane protein, osteoclast stimulatory transmembrane protein (OC‐STAMP), and analyzed its function. OC‐STAMP–deficient mice exhibited a complete lack of cell–cell fusion of osteoclasts and foreign body giant cells (FBGCs), both of which are macrophage‐lineage multinuclear cells, although expression of dendritic cell specific transmembrane protein (DC‐STAMP), which is also essential for osteoclast/FBGC fusion, was normal. Crossing OC‐STAMP–overexpressing transgenic mice with OC‐STAMP–deficient mice restored inhibited osteoclast and FBGC cell–cell fusion seen in OC‐STAMP–deficient mice. Thus, fusogenic mechanisms in macrophage‐lineage cells are regulated via OC‐STAMP and DC‐STAMP.


Biochemical and Biophysical Research Communications | 2008

Vascular endothelial growth factor-A is a survival factor for nucleus pulposus cells in the intervertebral disc

Nobuyuki Fujita; Jun-ichi Imai; Toru Suzuki; Masayuki Yamada; Ken Ninomiya; Kana Miyamoto; Ryotaro Iwasaki; Hideo Morioka; Morio Matsumoto; Kazuhiro Chiba; Shinya Watanabe; Toshio Suda; Yoshiaki Toyama; Takeshi Miyamoto

The intervertebral disc (IVD) is composed of two avascular tissue types, the nucleus pulposus (NP) and the annulus fibrosus (AF). IVDs is the largest avascular tissue in the human body, however, how these tissues are maintained without a blood supply is poorly understood. Here we show that vascular endothelial growth factor-A (VEGF-A) is highly expressed in NP and that VEGF-A plays a role in NP survival. High VEGF-A expression in NP was detected by microarray analysis, and NP was positive for the hypoxic probe pimonidazole and hypoxia-responsive genes. VEGF-A expression in NP was promoted by hypoxic conditions in vitro. NP cells also expressed the membrane-bound VEGF receptor-1 (VEGFR-1), and the number of apoptotic cells in cultured cell model of NP increased following treatment with VEGFR-1-Fc, which traps VEGF-A in NP. These results indicate that NP is a hypoxic tissue, and that VEGF-A functions in NP survival in an autocrine/paracrine manner.


Biochemical and Biophysical Research Communications | 2009

MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner

Kana Miyamoto; Ken Ninomiya; Koh-Hei Sonoda; Yoshiteru Miyauchi; Hiroko Hoshi; Ryotaro Iwasaki; Hiroya Miyamoto; Shigeyuki Yoshida; Yuiko Sato; Hideo Morioka; Kazuhiro Chiba; Kensuke Egashira; Toshio Suda; Yoshiaki Toyama; Takeshi Miyamoto

Monocyte chemoattractant protein-1 (MCP-1) is a chemokine that plays a critical role in the recruitment and activation of leukocytes. Here, we describe that multinuclear osteoclast formation was significantly inhibited in cells derived from MCP-1-deficient mice. MCP-1 has been implicated in the regulation of osteoclast cell-cell fusion; however defects of multinuclear osteoclast formation in the cells from mice deficient in DC-STAMP, a seven transmembrane receptor essential for osteoclast cell-cell fusion, was not rescued by recombinant MCP-1. The lack of MCP-1 in osteoclasts resulted in a down-regulation of DC-STAMP, NFATc1, and cathepsin K, all of which were highly expressed in normal osteoclasts, suggesting that osteoclast differentiation was inhibited in MCP-1-deficient cells. MCP-1 alone did not induce osteoclastogenesis, however, the inhibition of osteoclastogenesis in MCP-1-deficient cells was restored by addition of recombinant MCP-1, indicating that osteoclastogenesis was regulated in an autocrine/paracrine manner by MCP-1 under the stimulation of RANKL in osteoclasts.


Biochemical and Biophysical Research Communications | 2008

Cell fusion in osteoclasts plays a critical role in controlling bone mass and osteoblastic activity

Ryotaro Iwasaki; Ken Ninomiya; Kana Miyamoto; Toru Suzuki; Yuiko Sato; Hiromasa Kawana; Taneaki Nakagawa; Toshio Suda; Takeshi Miyamoto

The balance between osteoclast and osteoblast activity is central for maintaining the integrity of bone homeostasis. Here we show that mice lacking dendritic cell specific transmembrane protein (DC-STAMP), an essential molecule for osteoclast cell-cell fusion, exhibited impaired bone resorption and upregulation of bone formation by osteoblasts, which do not express DC-STAMP, which led to increased bone mass. On the contrary, DC-STAMP over-expressing transgenic (DC-STAMP-Tg) mice under the control of an actin promoter showed significantly accelerated cell-cell fusion of osteoclasts and bone resorption, with decreased osteoblastic activity and bone mass. Bone resorption and formation are known to be regulated in a coupled manner, whereas DC-STAMP regulates bone homeostasis in an un-coupled manner. Thus our results indicate that inhibition of a single molecule provides both decreased osteoclast activity and increased bone formation by osteoblasts, thereby increasing bone mass in an un-coupled and a tissue specific manner.


International Immunology | 2008

The role of DC-STAMP in maintenance of immune tolerance through regulation of dendritic cell function.

Yumi Sawatani; Takeshi Miyamoto; Shigenori Nagai; Mikako Maruya; Jun Imai; Kana Miyamoto; Nobuyuki Fujita; Ken Ninomiya; Toru Suzuki; Ryotaro Iwasaki; Yoshiaki Toyama; Masanori Shinohara; Shigeo Koyasu; Toshio Suda

Regulation of dendritic cell (DC) function is critical for maintaining self-tolerance and preventing autoimmunity. The dendritic cell-specific transmembrane protein (DC-STAMP) plays a key role in cell-cell fusion of osteoclasts and foreign body giant cells, but though originally identified in DCs, its specific roles there remain undefined. Here, we report that aged DC-STAMP-deficient mice display several systemic autoimmune symptoms such as spontaneous lymphoproliferation, splenomegaly associated with infiltration of T cells in several organs and increased serum anti-double-stranded DNA antibody production. Although a lack of DC-STAMP did not inhibit DC differentiation or proliferation, antigen presentation activity of DC-STAMP-deficient DCs was significantly up-regulated in both class I and II pathways through increased phagocytotic activity compared with wild-type DCs, an activity likely leading to autoimmunity. Our results indicate that DC-STAMP is required for proper regulation of DC activity and maintenance of immune self-tolerance.


Journal of Bone and Mineral Research | 2012

Aldehyde-stress resulting from Aldh2 mutation promotes osteoporosis due to impaired osteoblastogenesis

Hiroko Hoshi; Wu Hao; Yoshinari Fujita; Atsushi Funayama; Yoshiteru Miyauchi; Kazuaki Hashimoto; Kana Miyamoto; Ryotaro Iwasaki; Yuiko Sato; Tami Kobayashi; Hiroya Miyamoto; Shigeyuki Yoshida; Tomoaki Mori; Hiroya Kanagawa; Eri Katsuyama; Atsuhiro Fujie; Kyoko Kitagawa; Keiichi I. Nakayama; Toshihiro Kawamoto; Motoaki Sano; Keiichi Fukuda; Ikuroh Ohsawa; Shigeo Ohta; Hideo Morioka; Morio Matsumoto; Kazuhiro Chiba; Yoshiaki Toyama; Takeshi Miyamoto

Osteoporosis is a complex disease with various causes, such as estrogen loss, genetics, and aging. Here we show that a dominant‐negative form of aldehyde dehydrogenase 2 (ALDH2) protein, ALDH2*2, which is produced by a single nucleotide polymorphism (rs671), promotes osteoporosis due to impaired osteoblastogenesis. Aldh2 plays a role in alcohol‐detoxification by acetaldehyde‐detoxification; however, transgenic mice expressing Aldh2*2 (Aldh2*2 Tg) exhibited severe osteoporosis with increased levels of blood acetaldehyde without alcohol consumption, indicating that Aldh2 regulates physiological bone homeostasis. Wild‐type osteoblast differentiation was severely inhibited by exogenous acetaldehyde, and osteoblastic markers such as osteocalcin, runx2, and osterix expression, or phosphorylation of Smad1,5,8 induced by bone morphogenetic protein 2 (BMP2) was strongly altered by acetaldehyde. Acetaldehyde treatment also inhibits proliferation and induces apoptosis in osteoblasts. The Aldh2*2 transgene or acetaldehyde treatment induced accumulation of the lipid‐oxidant 4‐hydroxy‐2‐nonenal (4HNE) and expression of peroxisome proliferator‐activated receptor gamma (PPARγ), a transcription factor that promotes adipogenesis and inhibits osteoblastogenesis. Antioxidant treatment inhibited acetaldehyde‐induced proliferation‐loss, apoptosis, and PPARγ expression and restored osteoblastogenesis inhibited by acetaldehyde. Treatment with a PPARγ inhibitor also restored acetaldehyde‐mediated osteoblastogenesis inhibition. These results provide new insight into regulation of osteoporosis in a subset of individuals with ALDH2*2 and in alcoholic patients and suggest a novel strategy to promote bone formation in such osteopenic diseases.

Collaboration


Dive into the Ryotaro Iwasaki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Toshio Suda

National University of Singapore

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge